Monoferric denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for monoferric are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Issue a "Not FDA-Approved" Denial for Monoferric

This denial type is worth examining carefully. Monoferric (ferric derisomaltose) received FDA approval for use in adults with iron-deficiency anemia in the United States. A "not FDA-approved" denial for Monoferric may therefore reflect one of three situations: (1) the claim was filed under a code or indication that triggered an automated flag; (2) the plan is applying the denial to an off-label use of the drug for a condition outside the FDA-approved indication; or (3) there was an administrative coding error. Before appealing on clinical grounds, confirm which situation applies.

## Why This Denial Is Appealable

If Monoferric is being prescribed within its FDA-approved indication and the denial is in error, the appeal is straightforward: produce the FDA approval documentation and the correct ICD/CPT coding. If the denial concerns an off-label use, note that most state and federal rules — and Aetna's own policies — require coverage of off-label uses that are supported by one or more recognized compendia (e.g., Micromedex, DrugDex, AHFS Drug Information) or major peer-reviewed literature. Off-label denial appeals should cite the compendium support.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal within the deadline shown on your denial letter. Include the FDA product label and any compendium entries.
• External review (ACA §2719): Available after internal exhaustion. An independent reviewer — not Aetna — issues a binding decision. The window is approximately 4 months from final internal denial.
• Expedited review: Available for urgent medical situations; response required within 72 hours.

## Documentation to Gather

1. FDA approval confirmation — the current FDA-approved prescribing information (label) for Monoferric, available at DailyMed/FDA.gov. 2. Prescribed indication — confirm in writing that the prescriber is ordering the drug for its approved indication, and document that in the appeal. 3. Correct billing codes — request that your prescriber's billing office verify the diagnosis and procedure codes submitted. 4. Compendia support (if off-label) — obtain a current compendium listing supporting the off-label use, plus any relevant peer-reviewed citations. 5. Prescriber letter — explaining the clinical rationale and the indication being treated.

## Criteria-Mapping Structure

Obtain the exact denial language from Aetna's denial letter. If it cites a policy number or clinical criteria, request the full policy text. Map each stated reason to a factual rebuttal — FDA label page, compendia entry, or coding correction. Submit all supporting documents in a single, organized packet to reduce back-and-forth delays.